CRIS Current Research Information System

FABBRI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.101
AS - Asia 7.185
EU - Europa 4.406
SA - Sud America 593
Continente sconosciuto - Info sul continente non disponibili 425
AF - Africa 318
OC - Oceania 20
Totale 21.048
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.886
SG - Singapore 2.067
CN - Cina 1.928
VN - Vietnam 1.176
IT - Italia 933
GB - Regno Unito 776
FR - Francia 638
DE - Germania 598
HK - Hong Kong 595
SE - Svezia 502
BR - Brasile 459
IN - India 340
BD - Bangladesh 295
KR - Corea 261
RU - Federazione Russa 218
IE - Irlanda 169
JP - Giappone 147
CA - Canada 111
NL - Olanda 94
AT - Austria 79
ZA - Sudafrica 78
ID - Indonesia 74
SC - Seychelles 67
CI - Costa d'Avorio 64
FI - Finlandia 59
AR - Argentina 57
UA - Ucraina 50
EE - Estonia 48
JO - Giordania 48
MX - Messico 48
TG - Togo 48
PL - Polonia 40
IQ - Iraq 37
CH - Svizzera 34
BG - Bulgaria 32
PH - Filippine 30
TR - Turchia 29
TH - Thailandia 25
PK - Pakistan 24
CO - Colombia 21
EC - Ecuador 21
BE - Belgio 19
ES - Italia 19
AU - Australia 18
GR - Grecia 17
JM - Giamaica 16
UZ - Uzbekistan 16
SA - Arabia Saudita 15
IL - Israele 14
HU - Ungheria 13
CZ - Repubblica Ceca 12
MA - Marocco 11
CR - Costa Rica 10
DK - Danimarca 10
TW - Taiwan 10
MY - Malesia 9
TN - Tunisia 9
VE - Venezuela 9
AZ - Azerbaigian 8
EG - Egitto 8
ET - Etiopia 7
EU - Europa 7
PY - Paraguay 7
LB - Libano 6
LT - Lituania 6
NO - Norvegia 6
PE - Perù 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
PA - Panama 5
RO - Romania 5
SK - Slovacchia (Repubblica Slovacca) 5
DZ - Algeria 4
GH - Ghana 4
HR - Croazia 4
IR - Iran 4
KE - Kenya 4
NP - Nepal 4
SV - El Salvador 4
SY - Repubblica araba siriana 4
AL - Albania 3
BO - Bolivia 3
BW - Botswana 3
GT - Guatemala 3
HN - Honduras 3
KG - Kirghizistan 3
NG - Nigeria 3
NI - Nicaragua 3
SI - Slovenia 3
UY - Uruguay 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
LK - Sri Lanka 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PR - Porto Rico 2
Totale 20.601
Salva come PNG Salva come JPEG
Città #
Singapore 1.389
Ashburn 760
Fairfield 667
Southend 633
Hefei 594
Hong Kong 551
San Jose 478
Santa Clara 367
Seattle 295
Woodbridge 286
Cambridge 278
Hanoi 262
Ho Chi Minh City 262
Seoul 252
Wilmington 250
Chandler 243
Houston 237
Council Bluffs 232
Princeton 215
Los Angeles 213
Dallas 201
Beijing 183
Bologna 181
Ann Arbor 178
Boardman 177
Dublin 166
Lauterbourg 154
New York 130
Tokyo 129
Dong Ket 104
Frankfurt am Main 82
Buffalo 81
Abidjan 64
Westminster 63
San Diego 58
Bengaluru 57
Nanjing 57
Rome 55
Haiphong 53
Padova 52
São Paulo 51
Redondo Beach 50
Milan 49
Vienna 49
Jakarta 48
Lomé 48
Chicago 47
Amman 46
Berlin 46
Turin 46
Da Nang 42
The Dalles 41
London 37
Shenyang 36
Helsinki 35
Guangzhou 34
Shanghai 34
San Francisco 33
Nuremberg 32
Phoenix 32
Jinan 30
Montreal 30
Saint Petersburg 30
Naples 29
Orem 29
Sofia 29
Atlanta 27
Boston 25
Olalla 25
Warsaw 25
Paris 23
Bern 22
Hebei 22
Mülheim 22
Tianjin 22
Tongling 21
Munich 20
Nanchang 20
North Charleston 20
Baghdad 19
Bühl 19
Changsha 19
Denver 19
Des Moines 19
Lappeenranta 18
Mexico City 18
Toronto 18
Xi'an 18
Brooklyn 17
Palermo 17
Wuhan 17
Brasília 15
Hangzhou 15
Biên Hòa 14
Chennai 14
Hải Dương 14
Jacksonville 14
Jiaxing 14
Walnut Creek 14
Amsterdam 13
Totale 12.341
Salva come PNG Salva come JPEG
Nome #
Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis 603
Hyperthyroidism and depression: a clinical case of atypical thyrotoxicosis manifestation 568
Genetica dei comportamenti impulsivo-aggressivi: possibile applicazione in psichiatria forense? 456
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone 388
The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges 241
Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. 225
CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: Results from the Munich Antidepressant Response Signature (MARS) study 222
The bidirectional interaction between antidepressants and the gut microbiota: are there implications for treatment response? 219
Age of onset in schizophrenia spectrum disorders: Complex interactions between genetic and environmental factors 213
Specific symptomatology profile associated with treatment resistant depression: A multicentric study from the Group for the Study of Resistant Depression with a focus on sex 212
A model to investigate SNPs' interaction in GWAS studies 197
Hypomanic symptoms in major depressive disorder: Prognostic impact and treatment issues 194
The comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: A 6-month, open-label, randomized controlled pilot trial 189
A machine learning approach to predict treatment efficacy and adverse effects in major depression using CYP2C19 and clinical-environmental predictors 183
Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial 180
Progress and prospects in pharmacogenetics of antidepressant drugs 180
Association between CANCA1C gene rs1034936 polymorphism and alcohol dependence in bipolar disorder 177
Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: A 6-month, open-label, randomized, pilot trial 174
Anhedonia is associated with a specific depression profile and poor antidepressant response 173
TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. 173
Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response 169
Cariprazine specificity profile in the treatment of acute schizophrenia: A meta-Analysis and meta-regression of randomized-controlled trials 167
Exploring the use of immunomethylomics in the characterization of depressed patients: A proof-of-concept study 166
Neuronal cell adhesion genes and antidepressant response in three independent samples 166
Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance 165
Epigenetic basis of psychiatric disorders: a narrative review 164
The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives 159
HTR1A polymorphisms and clinical efficacy of antipsychotic drug treatment in schizophrenia: A meta-analysis 158
Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance 156
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. 153
Clinical features and drug induced side effects in early versus late antidepressant responders. 151
22q11.2 rearrangements: clinical and research implications of population-based risk of neuropsychiatric and developmental disorders 151
Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR(⁎)D. 150
Mirtazapine blood levels and antidepressant response 148
Pharmacogenetics in major depression: a comprehensive meta-analysis. 147
Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients 147
HTR1A gene polymorphisms and 5-HT1A receptor partial agonist antipsychotics efficacy in Schizophrenia 147
Anxiety disorders and age-related changes in physiology 146
Insulin resistance and poorer treatment outcomes in depression: evidence from UK Biobank primary care data 146
Genome-wide association study of antidepressant response: Involvement of the inorganic cation transmembrane transporter activity pathway 145
Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. 143
Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts 142
Obsessive-Compulsive, Psychotic, and Autism Dimensions Overlap in Real World: A Case Report 142
Predictors of switch from depression to mania in bipolar disorder 142
Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study 142
No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression. 141
Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. 141
Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank 140
Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study 140
Genetic basis of Bipolar disorder 139
Mechanisms of antidepressant action: an integrated dopaminergic perspective. 138
Pharmacogenetics of antidepressants. 138
Pharmacogenetics in Psychiatry 138
Genetics of serotonin receptors and depression: state of the art. 136
Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials 134
Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation 133
Schizophrenia-Like Symptoms in Narcolepsy Type 1: Shared and Distinctive Clinical Characteristics 133
Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder 132
The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs 131
Polygenic risk scores for neuropsychiatric, inflammatory, and cardio-metabolic traits highlight possible genetic overlap with suicide attempt and treatment-emergent suicidal ideation 130
Clinical insights into the cross-link between mood disorders and type 2 diabetes: A review of longitudinal studies and Mendelian randomisation analyses 130
Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns 130
Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients 130
Genetics of resilience: Implications from genome-wide association studies and candidate genes of the stress response system in posttraumatic stress disorder and depression 130
Genetic variants associated with psychotic symptoms across psychiatric disorders 129
Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder 127
Shared genetics among major psychiatric disorders. 124
Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression 124
Comparison of Mortality Rates between Italian and Foreign-born Patients with Alcohol Use Disorders 124
Pharmacogenetics of antidepressant response. 123
The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder 122
The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation? 122
DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy 122
Genetics of long-term treatment outcome in bipolar disorder 122
Biomarkers of treatment-resistant schizophrenia: A systematic review 121
The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries 121
Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies 121
Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies 121
Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: Common and specific effects of key regulators of fat-mass homoeostasis genes 120
Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples 119
Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder 117
Identifying the Common Genetic Basis of Antidepressant Response 116
The link between cognition and somatic conditions related to insulin resistance in the UK Biobank study cohort: a systematic review 116
Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder 116
Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. 116
Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder 115
Age as a moderating factor of treatment resistance in depression 115
Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications 114
Imputed expression of schizophrenia-associated genes and cognitive measures in patients with schizophrenia 113
Pharmacogenetics and depression: A critical perspective 113
Refining prediction in treatment-resistant depression: Results of machine learning analyses in the TRD III sample 112
Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice 112
Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder 112
Clinical, demographic, and genetic risk factors of treatment-attributed suicidality in >10,000 Australian adults taking antidepressants 110
Genetics in psychiatry: Methods, clinical applications and future perspectives 109
Multimodal brain-derived subtypes of Major depressive disorder differentiate patients for anergic symptoms, immune-inflammatory markers, history of childhood trauma and treatment-resistance 108
Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials 108
Is Pharmacogenetics Useful in Antidepressant Treatment? 107
Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression 107
Correlation between emotion dysregulation and mood symptoms of bipolar disorder: A systematic review and meta-analysis 105
Totale 15.746
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.599
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.599
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.605 0 85 82 52 154 122 48 256 75 140 311 280
2022/20231.881 170 229 118 176 111 149 111 142 344 54 164 113
2023/2024696 46 115 53 63 45 84 69 62 30 68 38 23
2024/20253.450 74 373 220 221 531 215 249 116 117 258 322 754
2025/20268.249 589 977 964 642 640 382 993 407 1.297 529 505 324
2026/20271.583 974 609 0 0 0 0 0 0 0 0 0 0
Totale 21.048